The signing ceremony was a significant event during the French President’s state visit to Vietnam, at the invitation of State President Luong Cuong. This visit holds extraordinary importance as the two nations recently elevated their relationship to a Comprehensive Strategic Partnership in October 2024, during the official visit of General Secretary To Lam to France.
The announcement of the collaboration between VNVC and Sanofi on vaccine production technology transfer is a vivid testament to the mutual trust and dedication of both parties, marking a significant step towards new heights in essential fields of the globalized era, such as healthcare and wellness.
Mr. Ngo Chi Dung, CEO and Chairman of Vietnam Vaccine Company (VNVC), and Ms. Zainab Sadat Qayyum, Sanofi’s Vice President for Southeast Asia and India, exchanged the agreement on Sanofi’s vaccine technology transfer at the VNVC Vaccine and Biological Products Factory, witnessed by State President Luong Cuong and French President Emmanuel Macron. Photo: Hai Nam
In a press conference following the document exchange, State President Luong Cuong remarked that Vietnam and France have acknowledged cooperation in traditional fields, science and technology, healthcare, education, and numerous developmental aspects within the context of their new relationship. The two countries agreed to strengthen cooperation in areas of mutual strength, including aerospace, nuclear energy, artificial intelligence, digital transformation, pharmaceuticals, and technology transfer.
Consequently, the vaccine production technology transfer agreement between VNVC and Sanofi, a leading French pharmaceutical group, concretely demonstrates the strategic collaboration between the two nations, laying the foundation for bilateral development in the healthcare sector, encompassing not only commerce and human resource training but also expanding and elevating cooperation in scientific research, technology transfer, and high-tech vaccine production. The collaboration is expected to bring substantial and long-term benefits to the healthcare and wellness of both nations’ populations while providing impetus and a solid legal basis for bilateral activities in healthcare, pharmaceuticals, and vaccines in the future.
This milestone also signifies a crucial step for Vietnam’s healthcare sector in expanding international cooperation in advanced science and technology, gradually taking proactive measures to strengthen national healthcare security, enhance resilience to future pandemic challenges, and establish a robust foundation for remarkable progress in the life sciences, ultimately benefiting the people.
According to the cooperation agreement, VNVC and Sanofi will gradually transfer technology to produce several of Sanofi’s important vaccines in large quantities in Vietnam. Additionally, Sanofi will accompany VNVC in training human resources and ensuring quality management in vaccine research and production.
Commenting on the significance of this collaboration, Mr. Ngo Chi Dung, CEO and Chairman of VNVC, stated that in the context of the Party and State creating the most favorable conditions for the development of the private sector, especially in international science and technology cooperation, the technology transfer collaboration with Sanofi, a world-leading vaccine manufacturer, is of great importance. It helps VNVC, in particular, and Vietnam’s vaccine industry, in general, swiftly enhance its capacity to produce high-quality “Made in Vietnam” vaccines equivalent to global standards. Technology transfer enables Vietnam to rapidly access cutting-edge modern technologies, optimize research and development activities, timely serve domestic demands, and firmly safeguard national healthcare security.
“The cooperation agreement with Sanofi, a pharmaceutical group with over 100 years of experience and global influence, offers Vietnam the opportunity to access world-leading vaccine production technology. This enables us to proactively produce hundreds of millions of doses of high-quality vaccines annually to meet domestic demands and even for export. Local production will ensure a sufficient supply of high-quality vaccines for our people and reduce vaccine costs. This holds tremendous significance in our vaccine coverage strategy to protect the health of our entire population, thereby reducing the burden of diseases, lowering healthcare costs, and improving the quality of life,” Mr. Ngo Chi Dung expressed his expectation.
Each year, the VNVC Vaccination System serves tens of millions of customers with high-quality vaccines, safely stored according to international standards, at reasonable prices, thus making a significant contribution to preventing infectious diseases among the people and the community.
With a strategic vision of contributing to the goal of national vaccine self-sufficiency, VNVC will construct a modern VNVC Vaccine and Biological Products Factory with a scale of up to 26,000 square meters in Long An province. With an initial investment of 2,000 billion VND, the VNVC vaccine factory is designed to meet the most advanced Good Manufacturing Practice (GMP) standards of the World Health Organization (WHO), the European Union (EU), and the US Food and Drug Administration (FDA).
Currently, Sanofi provides tens of millions of doses of high-quality vaccines to meet the needs of Vietnam’s vaccination services, including the 6-in-1 Hexaxim, 4-in-1 Tetraxim, 3-in-1 diphtheria-tetanus-pertussis vaccine Adacel, rabies vaccine Verorab, meningococcal vaccine Menactra, hepatitis A vaccine Avaxim, quadrivalent flu vaccine Vaxigrip Tetra, and typhoid vaccine Typhim VI.
Most of these vaccines are supplied and safely administered at VNVC’s network of over 220 vaccination centers nationwide, with preferential pricing policies. It is anticipated that when these vaccines are produced at the VNVC factory, Vietnam will have an abundant supply and reduced costs, providing opportunities for comprehensive vaccination and improved health protection for many children and adults.
Crafting and Trading Counterfeit Medicines: A Heinous Act of Mass Murder
“The severe consequences of counterfeit medicine and vaccine production and trafficking cannot be overstated. We must take a firm stand against these heinous crimes. To deter such despicable acts, lawmakers are proposing the harshest penalties, including the death sentence, for those found guilty of producing and trading fake food products, particularly fake milk and supplements.”
Enhancing Vietnam – Japan Economic Partnership
“Amidst global economic challenges, particularly the backdrop of the US countervailing duty policy, strengthening the Vietnam-Japan Comprehensive Strategic Partnership is of paramount importance for the socio-economic development of both nations.”
What Do Investors Say About The Son Hai Group’s Opposition To The Highway Contractor Selection Results?
The investor affirms that they have not received any formal complaints regarding the results of the contractor selection for the Ho Chi Minh City – Thu Dau Mot – Chon Thanh expressway project.
The University of Technology and VNG Corporation: Nurturing a Dynamic Trio Partnership.
On May 24th, the Ho Chi Minh City National University launched a program titled “Resolution No. 57-NQ/TW: From Vision to Action – A Collaborative Model for Government, Academia, and Enterprise.”
“Vietnamese Private Sector: No Need for Praises, Just Treat Them as the Norm”
The private sector in Vietnam has faced numerous challenges, but the introduction of Resolution 68 has been a game-changer. This pivotal resolution has unlocked a world of opportunities, acting as a key to overcoming obstacles and paving the way for remarkable growth and transformation within the private sector. It has truly been a catalyst for shaping the nation’s economy and fostering a thriving business environment.
